Feature

Targeting B-cell signaling pathways: a central role for Bruton’s tyrosine kinase


 

B-cell cancers constitute a large group of diseases with diverse clinical and pathological characteristics that arise from the B (bursal- or bone marrow-derived) lymphocytes of the immune system. B cells are involved in humoral immunity as part of the adaptive immune response. They display a unique B-cell receptor (BCR) on their surface which binds to a specific antigen. Antigen- binding activates the process of clonal expansion, during which the B cell reproduces to form an army of clones that secrete the same antibody. These antibodies then bind to the target antigen on foreign cells and initiate a range of immune responses that ultimately lead to the destruction of that cell.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Predicting problems in families of cancer patients
MDedge Hematology and Oncology
Team reports new method of chemo delivery
MDedge Hematology and Oncology
Team reports new method of chemo delivery
MDedge Hematology and Oncology
Long-term complications after ALL minimal, study shows
MDedge Hematology and Oncology
Low-dose T-cell transfer can fight CMV
MDedge Hematology and Oncology
Tool may predict cancer patients’ risk of financial stress
MDedge Hematology and Oncology
Lipid instigates leukemic cell death
MDedge Hematology and Oncology
Restoring gene function can ‘reverse’ B-ALL
MDedge Hematology and Oncology
Switch to nilotinib improves deep molecular response in CML
MDedge Hematology and Oncology
Inhibitor shows promise for hematologic disorders
MDedge Hematology and Oncology